Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascletis PharmaASCLF 40 Cash-to-Debt is 368.20 as of Dec. 2025, which is 57% below its 10-year median of 846.67. GuruFocus rates ASCLF with a GF Score™ of 40/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,396 Biotechnology companies, Ascletis Pharma ranks better than 83.67% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ascletis Pharma's cash to debt ratio for the quarter that ended in Dec. 2025 was 368.20.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Ascletis Pharmacould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Ascletis Pharma's Cash-to-Debt or its related term are showing as below:
ASCLF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 255.13 Med: 846.67 Max: No Debt
Current: 368.48
During the past 10 years, Ascletis Pharma's highest Cash to Debt Ratio was No Debt. The lowest was 255.13. And the median was 846.67.
ASCLF's Cash-to-Debt is ranked better than 83.67% of 1396
companies
in the Biotechnology industry
Industry Median: 6.21
vs ASCLF: 368.48
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Ascletis Pharma Cash-to-Debt Related Terms
Ascletis Pharma Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASCLF vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Ascletis Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascletis Pharma (ASCLF) has a Cash-to-Debt of 368.20 as of Dec. 2025. This is 57% below median its historical median of 846.67. Over the past decade, Ascletis Pharma's Cash-to-Debt has ranged from 255.13 to 10,000.00. According to the industry distribution chart, Ascletis Pharma ranks #228 out of 1396 companies in the Biotechnology industry, placing it in the top 16.3%.
Is Ascletis Pharma's Cash-to-Debt too high?
Ascletis Pharma's current Cash-to-Debt of 368.20 is 57% below median its 10-year median of 846.67. Over the past 10 years, this metric has ranged from a low of 255.13 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.21. Ascletis Pharma's value of 368.20 is 5829.1% above this industry median. Based on the distribution chart, Ascletis Pharma ranks #228 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascletis Pharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #228 out of 1396 companies for Cash-to-Debt. This places Ascletis Pharma in the top 16% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 6.21. Ascletis Pharma's value of 368.20 is 5829.1% above this benchmark. Historically, Ascletis Pharma's own Cash-to-Debt has ranged from 255.13 to 10,000.00 over the past decade. While the company's 10-year median is 846.67 vs. the industry median of 6.21, Ascletis Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.21, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascletis Pharma's current Cash-to-Debt of 368.20 is 5829.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascletis Pharma's current Cash-to-Debt is 368.20, which is 57% below median its own 10-year median of 846.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.21 — trading 5925% above its estimated fair value. The current Cash-to-Debt is 368.20, which is 57% below median its 10-year median of 846.67 and 5829.1% above the Biotechnology industry median of 6.21. Ascletis Pharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current Cash-to-Debt is 368.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (ASCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.21 is trading 5925% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
Cash-to-Debt: 368.20 (57% below median its 10-year median of 846.67)
GF Value™: $0.02 vs. price of $1.21 (5925% above fair value)
Industry Position: 5829.1% above the Biotechnology median (#228 of 1396)
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
40GF Score
Get the complete analysis for ASCLF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 
